PDCD1 and head and neck squamous cell carcinoma: For resectable locally advanced HNSCC, clinical trials have evaluated neoadjuvant PD-1 inhibitors—either used as monotherapy or combined with paclitaxel/cisplatin or low-dose radiotherapy.